Published in Eur J Nucl Med Mol Imaging on January 25, 2012
Quantitative analysis and comparison study of [18F]AlF-NOTA-PRGD2, [18F]FPPRGD2 and [68Ga]Ga-NOTA-PRGD2 using a reference tissue model. PLoS One (2012) 1.05
Radiofluorination using aluminum-fluoride (Al18F). EJNMMI Res (2013) 0.96
Nanotheranostics for personalized medicine. Expert Rev Mol Diagn (2013) 0.96
(18)F-alfatide II and (18)F-FDG dual-tracer dynamic PET for parametric, early prediction of tumor response to therapy. J Nucl Med (2013) 0.94
Comparison of cyclic RGD peptides for αvβ3 integrin detection in a rat model of myocardial infarction. EJNMMI Res (2013) 0.94
MicroPET/CT imaging of αvβ₃ integrin via a novel ⁶⁸Ga-NOTA-RGD peptidomimetic conjugate in rat myocardial infarction. Eur J Nucl Med Mol Imaging (2013) 0.92
Application of (68)Ga-PRGD2 PET/CT for αvβ3-integrin imaging of myocardial infarction and stroke. Theranostics (2014) 0.90
Positron emission tomography imaging of CD105 expression in a rat myocardial infarction model with (64)Cu-NOTA-TRC105. Am J Nucl Med Mol Imaging (2013) 0.89
First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts. Nucl Med Biol (2013) 0.87
VEGF-loaded graphene oxide as theranostics for multi-modality imaging-monitored targeting therapeutic angiogenesis of ischemic muscle. Nanoscale (2013) 0.87
Imaging integrin alpha-v-beta-3 expression in tumors with an 18F-labeled dimeric RGD peptide. Contrast Media Mol Imaging (2013) 0.80
One-step (18)F labeling of non-peptidic bivalent integrin αvβ3 antagonist for cancer imaging. Bioconjug Chem (2015) 0.77
The role of molecular imaging in the evaluation of myocardial and peripheral angiogenesis. Ann Nucl Med (2015) 0.77
64Cu-DOTA as a surrogate positron analog of Gd-DOTA for cardiac fibrosis detection with PET: pharmacokinetic study in a rat model of chronic MI. Nucl Med Commun (2016) 0.77
Angiogenesis PET Tracer Uptake ((68)Ga-NODAGA-E[(cRGDyK)]₂) in Induced Myocardial Infarction in Minipigs. Diagnostics (Basel) (2016) 0.77
PET imaging in heart failure: the role of new tracers. Heart Fail Rev (2017) 0.77
Advanced tracers in PET imaging of cardiovascular disease. Biomed Res Int (2014) 0.76
Comparison of 18F-AIF-NOTA-PRGD2 and 18F-FDG uptake in lymph node metastasis of differentiated thyroid cancer. PLoS One (2014) 0.76
Stereotactic Comparison Study of (18)F-Alfatide and (18)F-FDG PET Imaging in an LLC Tumor-Bearing C57BL/6 Mouse Model. Sci Rep (2016) 0.75
3D cardiac microvessels embolization imaging based on X-ray phase contrast imaging. Biomed Eng Online (2014) 0.75
Identification of Angiogenesis Rich-Viable Myocardium using RGD Dimer based SPECT after Myocardial Infarction. Sci Rep (2016) 0.75
Clinical Utility and Future Applications of PET/CT and PET/CMR in Cardiology. Diagnostics (Basel) (2016) 0.75
Pharmacokinetics and microbiodistribution of 64Cu-labeled collagen-binding peptides in chronic myocardial infarction. Nucl Med Commun (2016) 0.75
Imaging of αvβ3 integrin expression in experimental myocardial ischemia with [(68)Ga]NODAGA-RGD positron emission tomography. J Transl Med (2017) 0.75
Molecular Imaging of Angiogenesis in Cardiac Regeneration. Curr Cardiovasc Imaging Rep (2016) 0.75
Pet Imaging and its Application in Cardiovascular Diseases. Methodist Debakey Cardiovasc J (2017) 0.75
SPECT and PET imaging of angiogenesis and arteriogenesis in pre-clinical models of myocardial ischemia and peripheral vascular disease. Eur J Nucl Med Mol Imaging (2016) 0.75
Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science (1994) 12.83
Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 9.51
Angiogenesis in wound healing. J Investig Dermatol Symp Proc (2000) 3.12
The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest (1999) 2.88
Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med (2006) 2.65
A novel method of 18F radiolabeling for PET. J Nucl Med (2009) 2.35
Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med (1999) 2.11
Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest (2004) 2.06
Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des (2008) 2.04
Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. J Am Coll Cardiol (2008) 1.97
(68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging (2008) 1.91
18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression. Mol Imaging Biol (2009) 1.90
Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex. Bioconjug Chem (2010) 1.76
Myofibroblasts in reperfused myocardial infarcts express the embryonic form of smooth muscle myosin heavy chain (SMemb). Cardiovasc Res (2000) 1.73
(68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging. Eur J Nucl Med Mol Imaging (2009) 1.69
Why integrin as a primary target for imaging and therapy. Theranostics (2011) 1.61
Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels. Radiology (2011) 1.59
Radiolabeled arginine-glycine-aspartic acid peptides to image angiogenesis in swine model of hibernating myocardium. JACC Cardiovasc Imaging (2008) 1.57
Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem (2011) 1.56
One-step radiosynthesis of ¹⁸F-AlF-NOTA-RGD₂ for tumor angiogenesis PET imaging. Eur J Nucl Med Mol Imaging (2011) 1.34
Molecular imaging of the kinetics of vascular endothelial growth factor gene expression in ischemic myocardium. Circulation (2004) 1.33
Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. J Am Chem Soc (2004) 1.32
Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med (2008) 1.32
18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy. J Nucl Med (2010) 1.28
Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc Res (2008) 1.21
In vivo molecular imaging of angiogenesis, targeting alphavbeta3 integrin expression, in a patient after acute myocardial infarction. Eur Heart J (2008) 1.14
Image-guided cardiac cell delivery using high-resolution small-animal ultrasound. Mol Ther (2005) 1.11
PET imaging of early response to the tyrosine kinase inhibitor ZD4190. Eur J Nucl Med Mol Imaging (2011) 1.08
Rapid and simple one-step F-18 labeling of peptides. Bioconjug Chem (2011) 1.06
Targeting angiogenesis to restore the microcirculation after reperfused MI. Nat Rev Cardiol (2009) 1.05
Integrin Targeted Imaging and Therapy. Theranostics (2011) 1.00
Molecular imaging of myocardial infarction. J Mol Cell Cardiol (2006) 0.99
Integrin-targeted imaging of inflammation in vascular remodeling. Arterioscler Thromb Vasc Biol (2011) 0.96
Early molecular imaging of interstitial changes in patients after myocardial infarction: comparison with delayed contrast-enhanced magnetic resonance imaging. J Nucl Cardiol (2010) 0.90
In vivo molecular imaging of myocardial angiogenesis using the alpha(v)beta3 integrin-targeted tracer 99mTc-RAFT-RGD. J Nucl Cardiol (2010) 0.90
High-thermoelectric performance of nanostructured bismuth antimony telluride bulk alloys. Science (2008) 7.34
In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol (2006) 6.93
Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nat Nanotechnol (2008) 6.41
Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett (2006) 5.63
Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl Acad Sci U S A (2008) 4.89
In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation (2006) 4.48
Multimodality molecular imaging of tumor angiogenesis. J Nucl Med (2008) 3.99
Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res (2008) 3.47
US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology (2008) 3.15
microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med (2005) 2.96
Nanoparticle-based theranostic agents. Adv Drug Deliv Rev (2010) 2.86
Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med (2007) 2.86
PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med (2008) 2.77
microPET-based biodistribution of quantum dots in living mice. J Nucl Med (2007) 2.76
Nanoplatforms for targeted molecular imaging in living subjects. Small (2007) 2.69
Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med (2006) 2.65
Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small (2009) 2.59
(64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med (2007) 2.50
PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials (2010) 2.31
Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging (2007) 2.31
Effects of cell number on teratoma formation by human embryonic stem cells. Cell Cycle (2009) 2.30
PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med (2007) 2.28
Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc Natl Acad Sci U S A (2008) 2.25
Comparison of different adult stem cell types for treatment of myocardial ischemia. Circulation (2008) 2.22
Differentiation, survival, and function of embryonic stem cell derived endothelial cells for ischemic heart disease. Circulation (2007) 2.21
PET of vascular endothelial growth factor receptor expression. J Nucl Med (2006) 2.18
Obligate ligation-gated recombination (ObLiGaRe): custom-designed nuclease-mediated targeted integration through nonhomologous end joining. Genome Res (2012) 2.12
In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res (2006) 2.09
Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des (2008) 2.04
Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjug Chem (2005) 2.01
Ultrahigh sensitivity carbon nanotube agents for photoacoustic molecular imaging in living mice. Nano Lett (2010) 2.00
Molecular imaging of bone marrow mononuclear cell homing and engraftment in ischemic myocardium. Stem Cells (2007) 1.93
Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology (2010) 1.92
(68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging (2008) 1.91
18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression. Mol Imaging Biol (2009) 1.90
Comparison of reporter gene and iron particle labeling for tracking fate of human embryonic stem cells and differentiated endothelial cells in living subjects. Stem Cells (2008) 1.90
Ultrasmall c(RGDyK)-coated Fe3O4 nanoparticles and their specific targeting to integrin alpha(v)beta3-rich tumor cells. J Am Chem Soc (2008) 1.89
Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nat Protoc (2008) 1.87
A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression. J Nucl Med (2006) 1.83
How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther (2006) 1.81
Pulse accumulation, radial heat conduction, and anisotropic thermal conductivity in pump-probe transient thermoreflectance. Rev Sci Instrum (2008) 1.80
64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem (2007) 1.79
Quantum dot imaging for embryonic stem cells. BMC Biotechnol (2007) 1.78
Unusual magnetic properties of one-dimensional molecule-based magnets associated with a structural phase transition. Inorg Chem (2002) 1.78
Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis. Eur Heart J (2013) 1.77
Near-infrared fluorescent deoxyglucose analogue for tumor optical imaging in cell culture and living mice. Bioconjug Chem (2006) 1.75
(68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging. Eur J Nucl Med Mol Imaging (2009) 1.69
Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapy. Acc Chem Res (2011) 1.69
Upconversion nanoparticles: design, nanochemistry, and applications in theranostics. Chem Rev (2014) 1.68
Development of a controlled vocabulary and software application to analyze fruit shape variation in tomato and other plant species. Plant Physiol (2006) 1.64
Click chemistry for (18)F-labeling of RGD peptides and microPET imaging of tumor integrin alphavbeta3 expression. Bioconjug Chem (2007) 1.64
Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem (2006) 1.64
Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev (2010) 1.63
Why integrin as a primary target for imaging and therapy. Theranostics (2011) 1.61
High-affinity peptide against MT1-MMP for in vivo tumor imaging. J Control Release (2011) 1.59
Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels. Radiology (2011) 1.59
Survivin: a novel player in insulin cardioprotection against myocardial ischemia/reperfusion injury. J Mol Cell Cardiol (2010) 1.58
Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. Stem Cells (2009) 1.58
Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem (2011) 1.56
Oxorhenium(V) complexes containing tridentate Schiff-base and monothiol coligands. Inorganica Chim Acta (2000) 1.56
Positron emission tomography imaging of conditional gene activation in the heart. J Mol Cell Cardiol (2007) 1.56
Light-triggered theranostics based on photosensitizer-conjugated carbon dots for simultaneous enhanced-fluorescence imaging and photodynamic therapy. Adv Mater (2012) 1.56
Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur J Nucl Med Mol Imaging (2008) 1.55
Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model. J Nucl Med (2012) 1.52
Effects of epigenetic modulation on reporter gene expression: implications for stem cell imaging. FASEB J (2005) 1.52
[18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging (2007) 1.50
Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res (2008) 1.49
Characterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging. Acta Radiol (2009) 1.49
Integrin targeting for tumor optical imaging. Theranostics (2011) 1.47
In vivo imaging of embryonic stem cells reveals patterns of survival and immune rejection following transplantation. Stem Cells Dev (2008) 1.46
Effects of nanoparticle size on cellular uptake and liver MRI with polyvinylpyrrolidone-coated iron oxide nanoparticles. ACS Nano (2010) 1.46
microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med (2007) 1.46
Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers. Mol Imaging Biol (2006) 1.46
Experimental Cerenkov luminescence tomography of the mouse model with SPECT imaging validation. Opt Express (2010) 1.45
Relationship between particle mass and mobility for diesel exhaust particles. Environ Sci Technol (2003) 1.45
First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med (2013) 1.44
Long-term renal changes in the liver-specific glucokinase knockout mouse: implications for renal disease in maturity-onset diabetes of the young 2. Transl Res (2010) 1.44
Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. Angew Chem Int Ed Engl (2009) 1.44
Photosensitizer-loaded gold vesicles with strong plasmonic coupling effect for imaging-guided photothermal/photodynamic therapy. ACS Nano (2013) 1.44
Peptide-based probes for targeted molecular imaging. Biochemistry (2010) 1.43
A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging (2007) 1.43
Early prediction of organ failure under the revised Atlanta classification. Turk J Gastroenterol (2016) 1.43
DTNBP1, a schizophrenia susceptibility gene, affects kinetics of transmitter release. J Cell Biol (2008) 1.42
Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting. Biomaterials (2009) 1.42
A strategy for the proliferation of Ulva prolifera, main causative species of green tides, with formation of sporangia by fragmentation. PLoS One (2010) 1.42
The presence of the Y-chromosome, not the absence of the second X-chromosome, alters the mRNA levels stored in the fully grown XY mouse oocyte. PLoS One (2012) 1.42
Integrin targeted delivery of chemotherapeutics. Theranostics (2011) 1.42
Can insulin resistance be reversed by insulin therapy? Med Hypotheses (2008) 1.41
Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers. Mol Pharm (2009) 1.41
In vitro and in vivo antitumor effect of a trivalent bispecific antibody targeting ErbB2 and CD16. Cancer Biol Ther (2008) 1.40